Researchers from two labs in the Human Biology division at Fred Hutch Cancer Center recently published two studies aimed at better understanding how a notorious gene fusion — ZFTA-RELA — drives rare ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...

HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive ...

52-week follow-up data from type 1 diabetes (“T1D”) patients in COVALENT-112 who completed ≥80% of protocol-specified dosing with the read-out expected in the second quarter of 2026. 26-week primary ...

The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.

Senator Kirsten Gillibrand, a New York Democrat, said she is concerned about “sleeper cells” attacking within the U.S. amid the war in Iran. “I have very deep concerns about retaliatory attacks. I'm ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

To turbocharge disease-specific immune responses in patients, CAR-T cells are produced by removing a person's immune T cells ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Methods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients -- Single apheresis yields up to 5 billion (5×109) highly pure activated memory ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...